Targeted drug trial aims to block Cancer's growth signal

This study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial is for patients with various hard-to-treat cancers (like certain solid tumors, lymphomas, or myeloma) that have stopped responding to other treatments. Researchers are giving crizotinib, a pill taken twice daily, to see if blocking the faulty ROS1 protein helps control the cancer.